C
Christophe Tournigand
Researcher at Paris 12 Val de Marne University
Publications - 320
Citations - 13656
Christophe Tournigand is an academic researcher from Paris 12 Val de Marne University. The author has contributed to research in topics: Colorectal cancer & Cancer. The author has an hindex of 46, co-authored 280 publications receiving 11675 citations. Previous affiliations of Christophe Tournigand include University of Paris-Est & Pierre-and-Marie-Curie University.
Papers
More filters
Journal ArticleDOI
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study
Christophe Tournigand,Thierry André,Emmanuel Achille,Gérard Lledo,Michel Flesh,Dominique Méry-Mignard,E. Quinaux,C. Couteau,Marc Buyse,Gérard Ganem,B. Landi,Philippe Colin,Christophe Louvet,Aimery de Gramont +13 more
TL;DR: Both sequences achieved a prolonged survival and similar efficacy in metastatic colorectal cancer and the toxicity profiles were different.
Journal ArticleDOI
Potential of fecal microbiota for early‐stage detection of colorectal cancer
Georg Zeller,Julien Tap,Anita Y. Voigt,Shinichi Sunagawa,Jens Roat Kultima,Paul I. Costea,Aurelien Amiot,Jürgen Böhm,Francesco Brunetti,Nina Habermann,Rajna Hercog,Moritz Koch,Alain Luciani,Daniel R. Mende,Martin Schneider,Petra Schrotz-King,Christophe Tournigand,Jeanne Tran Van Nhieu,Takuji Yamada,Jürgen Zimmermann,Vladimir Benes,Matthias Kloor,Matthias Kloor,Matthias Kloor,Cornelia M. Ulrich,Cornelia M. Ulrich,Magnus von Knebel Doeberitz,Magnus von Knebel Doeberitz,Magnus von Knebel Doeberitz,Iradj Sobhani,Peer Bork,Peer Bork +31 more
TL;DR: CRC‐associated changes in the fecal microbiome at least partially reflected microbial community composition at the tumor itself, indicating that observed gene pool differences may reveal tumor‐related host–microbe interactions.
Journal ArticleDOI
OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study
Christophe Tournigand,Andrés Cervantes,Arie Figer,Gérard Lledo,M. Flesch,Marc Buyse,Laurent Mineur,Elisabeth Carola,Pierre-Luc Etienne,Fernando Rivera,Isabel Chirivella,N. Perez-Staub,Christophe Louvet,Thierry André,Isabelle Tabah-Fisch,Aimery de Gramont +15 more
TL;DR: Oxaliplatin can be safely stopped after six cycles in a FOLFOX regimen, and further study is needed to fully evaluate oxali Platin reintroduction.
Journal ArticleDOI
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study
Thierry André,Armand de Gramont,Dewi Vernerey,Benoist Chibaudel,Franck Bonnetain,Annemilaï Tijeras-Raballand,Aurelie Scriva,Tamas Hickish,Josep Tabernero,Jean-Luc Van Laethem,Maria Banzi,E. Maartense,Einat Shacham Shmueli,Göran Carlsson,Werner Scheithauer,Demetris Papamichael,Marcus Möehler,Stefania Landolfi,Pieter Demetter,Soudhir Colote,Christophe Tournigand,Christophe Louvet,Alex Duval,Jean François Fléjou,Aimery de Gramont +24 more
TL;DR: The OS benefit of oxaliplatin-based adjuvant chemotherapy, increasing over time and with the disease severity, was confirmed at 10 years in patients with stage II to III colon cancer, and updated results support the use of FOLFOX in Patients with stage III disease, including those with dMMR or BRAF mutation.
Journal ArticleDOI
Pooled Analysis of Safety and Efficacy of Oxaliplatin Plus Fluorouracil/Leucovorin Administered Bimonthly in Elderly Patients With Colorectal Cancer
Richard M. Goldberg,Isabelle Tabah-Fisch,Harry Bleiberg,Aimery de Gramont,Christophe Tournigand,Thierry André,Mace L. Rothenberg,E. Green,Daniel J. Sargent +8 more
TL;DR: FOLFOX4 maintains its efficacy and safety ratio in selected elderly patients with colorectal cancer and its judicious use should be considered without regard to patient age, although scant data are available among patients older than 80 years.